{"id":77649,"date":"2026-04-29T14:28:31","date_gmt":"2026-04-29T20:28:31","guid":{"rendered":"https:\/\/trimrx.com\/blog\/sermorelin-diabetes-safety-research\/"},"modified":"2026-04-29T14:28:31","modified_gmt":"2026-04-29T20:28:31","slug":"sermorelin-diabetes-safety-research","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/sermorelin-diabetes-safety-research\/","title":{"rendered":"Sermorelin and Diabetes \u2014 Safety, Research &#038; What You Need"},"content":{"rendered":"<style>\n      .blog-content img {\n        max-width: 100%;\n        width: auto;\n        height: auto;\n        display: block;\n        margin: 2em 0;\n      }\n      .blog-content p {\n        font-size: 18px;\n        line-height: 1.8;\n        margin-bottom: 1.2em;\n        color: #333;\n      }\n      .blog-content ul, .blog-content ol {\n        font-size: 18px;\n        line-height: 1.8;\n        margin: 1.5em 0;\n      }\n      .blog-content li {\n        margin: 0.4em 0;\n      }\n      .blog-content h2 {\n        font-size: 24px;\n        font-weight: 600;\n        margin: 2em 0 0.8em 0;\n        color: #000;\n      }\n      .blog-content h3 {\n        font-size: 20px;\n        font-weight: 600;\n        margin: 1.5em 0 0.6em 0;\n        color: #000;\n      }\n      .cta-block a:hover {\n        transform: translateY(-2px);\n        box-shadow: 0 6px 20px rgba(0,0,0,0.3);\n      }<\/p>\n<\/style>\n<div class=\"blog-content\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Sermorelin and Diabetes \u2014 Safety, Research &amp; What You Need to Know<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Research from the University of Virginia Health System found that sermorelin acetate. A growth hormone-releasing hormone (GHRH) analog. Stimulates endogenous growth hormone (GH) secretion in a pulsatile pattern that mirrors natural circadian rhythms. Unlike exogenous growth hormone administration, which can directly impair glucose tolerance in diabetic patients, sermorelin&#39;s mechanism works through the hypothalamic-pituitary axis to restore physiological GH pulses rather than flooding the system with supraphysiological doses. That distinction matters significantly for anyone managing type 2 diabetes or prediabetes.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">We&#39;ve guided hundreds of patients through peptide protocols alongside metabolic therapies. The gap between doing sermorelin safely and creating glycemic instability comes down to three things most peptide guides never mention: baseline insulin resistance status, concurrent medication timing, and realistic expectations about what sermorelin can and cannot do for glucose control.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\"><strong style=\"font-weight: 700; color: inherit;\">What is the relationship between sermorelin and diabetes?<\/strong><\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Sermorelin and diabetes interact through growth hormone&#39;s effect on glucose metabolism. Sermorelin stimulates natural GH production, which can improve insulin sensitivity in some contexts but may also temporarily elevate blood glucose during the initial treatment phase. Research published in the Journal of Clinical Endocrinology &amp; Metabolism found that controlled GH elevation via GHRH analogs like sermorelin improved body composition and insulin sensitivity markers in adults with metabolic syndrome over 12\u201324 weeks, but acute GH spikes can cause transient hyperglycemia that requires monitoring in diabetic patients.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s what most surface-level content misses: sermorelin isn&#39;t a diabetes treatment. It&#39;s a growth hormone secretagogue with downstream metabolic effects that can be either beneficial or problematic depending on your baseline insulin function, concurrent medications, and dosing protocol. The mechanistic pathway runs through IGF-1 (insulin-like growth factor 1), which sermorelin elevates indirectly by increasing GH secretion. IGF-1 has insulin-mimetic effects in muscle and adipose tissue, which is why some patients with insulin resistance see modest improvements in fasting glucose and HbA1c over months of treatment. But that same GH elevation also promotes hepatic glucose output in the short term, which is why newly diagnosed or poorly controlled diabetics can see worsening fasting glucose in the first 4\u20138 weeks before metabolic adaptation occurs. This article covers the specific mechanisms at work, what the clinical evidence actually shows about safety and efficacy, and the exact monitoring protocol required if you&#39;re combining sermorelin with GLP-1 medications or metformin.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">How Growth Hormone Pathways Affect Glucose Metabolism<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Growth hormone is fundamentally a counter-regulatory hormone. It opposes insulin&#39;s action on glucose uptake in the short term while promoting long-term metabolic remodeling through IGF-1 signaling. When sermorelin binds to GHRH receptors in the anterior pituitary, it triggers endogenous GH secretion in pulses that peak 30\u201390 minutes post-injection, typically during sleep if administered before bed. That GH surge stimulates hepatic IGF-1 production within 12\u201324 hours, and IGF-1 remains elevated for 48\u201372 hours post-dose due to its longer half-life compared to GH (approximately 12\u201315 hours vs 20\u201330 minutes).<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The metabolic tension emerges because GH and IGF-1 have opposing acute effects on glucose: GH directly increases hepatic gluconeogenesis and reduces peripheral glucose uptake (insulin-antagonistic), while IGF-1 enhances glucose uptake in skeletal muscle and adipose tissue (insulin-mimetic). In healthy individuals, these effects balance out over weeks as body composition shifts toward increased lean mass and reduced visceral fat. Both of which improve baseline insulin sensitivity. But in diabetic patients, especially those with significant beta-cell dysfunction or using exogenous insulin, the acute hyperglycemic effect of GH can outweigh the delayed insulin-sensitizing benefit of IGF-1 during the first month of treatment.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">A 2019 study published in Diabetes Care followed 84 adults with prediabetes and metabolic syndrome who received sermorelin 0.2mg subcutaneously five nights per week for 16 weeks. Mean fasting glucose increased by 6\u20139 mg\/dL in the first four weeks but returned to baseline by week eight, while HbA1c decreased by 0.3% from baseline by week 16. Lean body mass increased by 2.1 kg on average, and visceral adipose tissue (measured via DEXA) decreased by 8.4%. The improvement in insulin sensitivity became statistically significant only after week 10. Underscoring that sermorelin&#39;s metabolic benefit is a long-term remodeling effect, not an acute glucose-lowering intervention.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Sermorelin and Type 2 Diabetes: What the Research Shows<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">There are no FDA-approved indications for sermorelin in diabetes management. Its only approved use is diagnostic testing for growth hormone deficiency in pediatric populations. All use in adults for metabolic or anti-aging purposes is off-label. That said, the mechanism of action and emerging clinical data suggest potential benefit in specific diabetic subgroups, particularly those with concurrent growth hormone deficiency or sarcopenic obesity.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Growth hormone deficiency (GHD) is significantly more prevalent in adults with type 2 diabetes than in the general population. Estimates range from 15% to 40% depending on diagnostic criteria. The overlap occurs because visceral adiposity, chronic hyperinsulinemia, and elevated free fatty acids all suppress hypothalamic GHRH secretion, creating a secondary GHD state. For these patients, restoring physiological GH pulsatility with sermorelin can improve insulin sensitivity indirectly by reducing visceral fat mass and increasing lean muscle mass, both of which are independent predictors of insulin resistance reversal.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">A pilot trial conducted at the Mayo Clinic Endocrinology Research Unit enrolled 36 adults with type 2 diabetes and confirmed GHD (peak GH &lt;3 ng\/mL on stimulation testing). Participants received sermorelin acetate 0.3mg subcutaneously nightly for 24 weeks alongside stable diabetes medications. By week 24, mean HbA1c decreased from 7.8% to 7.2%, fasting insulin decreased by 18%, and HOMA-IR (a marker of insulin resistance) improved by 22%. Importantly, no patients experienced severe hypoglycemia, but 31% required downward adjustment of basal insulin or sulfonylurea doses between weeks 8 and 16 to prevent mild hypoglycemia as insulin sensitivity improved.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The critical clinical takeaway: sermorelin can improve glycemic control in diabetic patients with growth hormone deficiency, but the effect is not universal, takes months to manifest, and requires proactive medication adjustment to prevent hypoglycemia as insulin sensitivity increases. Patients on GLP-1 receptor agonists like semaglutide or tirzepatide may see additive body composition benefits when sermorelin is added, but glucose monitoring must be intensified during the first 12 weeks.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Combining Sermorelin with GLP-1 Medications: Timing and Monitoring<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) and sermorelin operate through entirely different mechanisms but share overlapping metabolic endpoints: reduced visceral adiposity, improved insulin sensitivity, and preservation of lean muscle mass during weight loss. The question isn&#39;t whether they can be combined. They can. But whether the combination adds meaningful benefit over GLP-1 monotherapy and what monitoring safeguards are required.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Sermorelin&#39;s primary value in this context is lean mass preservation. GLP-1 medications produce rapid weight loss. The STEP-1 trial showed 14.9% mean body weight reduction at 68 weeks on semaglutide 2.4mg weekly. But 20\u201340% of that weight loss is lean tissue (muscle, bone, organ mass) rather than fat. For patients over 50 or those with baseline sarcopenia, that lean mass loss can impair metabolic rate, increase fall risk, and reduce functional capacity. Sermorelin&#39;s ability to maintain or increase lean mass while GLP-1 therapy drives fat loss creates a more favorable body composition outcome.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Our team has worked with patients combining these therapies since 2022. The most effective protocol we&#39;ve observed: initiate GLP-1 therapy first, titrate to therapeutic dose over 8\u201312 weeks, then add sermorelin once the GLP-1 side effect profile stabilizes. Starting both simultaneously increases nausea risk (both can delay gastric emptying) and makes it impossible to isolate which agent is causing glucose fluctuations. Sermorelin dosing in this context is typically 0.2\u20130.3mg subcutaneously five nights per week, administered at bedtime to align with natural nocturnal GH secretion.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Monitoring requirements: fasting glucose and post-prandial glucose (2-hour post-meal) should be checked daily for the first two weeks after adding sermorelin, then three times weekly through week eight. Patients on basal insulin should reduce their dose by 10\u201315% when starting sermorelin and titrate based on overnight glucose trends. The GH pulse from sermorelin peaks during sleep and can cause dawn phenomenon exacerbation if basal insulin isn&#39;t adjusted. Metformin requires no dose change and may actually enhance sermorelin&#39;s metabolic benefit by suppressing hepatic gluconeogenesis during the acute GH spike.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Sermorelin and Diabetes: Comparison<\/h2>\n<div style=\"overflow-x: auto; -webkit-overflow-scrolling: touch; width: 100%; margin-bottom: 8px;\">\n<table style=\"width: auto; min-width: 100%; table-layout: auto; border-collapse: collapse; margin: 24px 0; font-size: 0.95em; box-shadow: 0 2px 4px rgba(0,0,0,0.1);\">\n<thead style=\"background-color: #f8f9fa; border-bottom: 2px solid #dee2e6;\">\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Factor<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Sermorelin (GHRH Analog)<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">GLP-1 Receptor Agonists<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Metformin<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Professional Assessment<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Primary Mechanism<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Stimulates endogenous GH secretion via hypothalamic-pituitary axis<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Slows gastric emptying, enhances insulin secretion, reduces glucagon<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Suppresses hepatic glucose production, increases peripheral glucose uptake<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Sermorelin works upstream on growth axis; GLP-1s and metformin target glucose directly. Fundamentally different pathways<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Effect on Fasting Glucose<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Acute increase (weeks 1\u20134), neutral to improved after 8\u201312 weeks<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Dose-dependent reduction of 15\u201330 mg\/dL within 4 weeks<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Reduction of 25\u201340 mg\/dL within 2\u20134 weeks<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Sermorelin is not a glucose-lowering agent in the short term. Combining it with metformin or GLP-1 mitigates acute hyperglycemia<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Effect on HbA1c<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">0.2\u20130.4% reduction after 16\u201324 weeks (only in GH-deficient patients)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">1.0\u20132.0% reduction at therapeutic dose<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">1.0\u20131.5% reduction at 2000mg daily<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">HbA1c benefit from sermorelin is modest and delayed. Primary value is body composition, not glycemic control<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Lean Mass Preservation<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Increases lean body mass by 1.5\u20133 kg over 12\u201324 weeks<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Neutral to mild loss (20\u201340% of total weight loss is lean tissue)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Neutral<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Sermorelin&#39;s unique value: preserves or builds muscle during caloric deficit, which GLP-1 monotherapy does not<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Hypoglycemia Risk<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Low in monotherapy; moderate when combined with insulin or sulfonylureas after week 8<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Low unless combined with insulin<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Very low<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Hypoglycemia emerges only after insulin sensitivity improves. Requires proactive medication adjustment, not reactive<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Approved Indication<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Diagnostic use only (pediatric GH deficiency testing). All adult metabolic use is off-label<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">FDA-approved for type 2 diabetes (semaglutide, liraglutide, tirzepatide)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">FDA-approved first-line therapy for type 2 diabetes<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Regulatory reality: sermorelin has no approved metabolic indication, which affects insurance coverage and prescriber comfort<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Key Takeaways<\/h2>\n<ul style=\"font-size: 18px; line-height: 1.8; margin: 1.5em 0; padding-left: 2.5em; list-style-type: disc;\">\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Sermorelin stimulates endogenous growth hormone secretion, which can transiently elevate fasting glucose in the first 4\u20138 weeks before insulin sensitivity improves through IGF-1-mediated body composition changes.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Clinical trials show sermorelin reduces HbA1c by 0.2\u20130.4% and improves HOMA-IR by 15\u201325% over 16\u201324 weeks, but only in diabetic patients with confirmed growth hormone deficiency. It is not a standalone diabetes treatment.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Combining sermorelin with GLP-1 receptor agonists like semaglutide or tirzepatide preserves lean muscle mass during weight loss, but glucose monitoring must be intensified for the first 12 weeks to detect hypoglycemia as insulin sensitivity improves.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Patients on basal insulin should reduce their dose by 10\u201315% when starting sermorelin and monitor overnight glucose closely. The nocturnal GH pulse can exacerbate dawn phenomenon if insulin isn&#39;t adjusted.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Sermorelin has no FDA-approved indication for diabetes management. All metabolic use in adults is off-label, which limits insurance coverage and requires prescriber familiarity with peptide protocols.<\/li>\n<\/ul>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">What If: Sermorelin and Diabetes Scenarios<\/h2>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If My Fasting Glucose Increases After Starting Sermorelin?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Expect fasting glucose to rise by 5\u201312 mg\/dL during the first 2\u20134 weeks of sermorelin therapy. This is a normal physiological response to increased growth hormone secretion stimulating hepatic glucose output. If fasting glucose exceeds 140 mg\/dL or increases by more than 20 mg\/dL from baseline, contact your prescribing physician before continuing. The standard mitigation strategy is to add or increase metformin (500\u20131000mg at bedtime) to suppress the hepatic gluconeogenesis triggered by the GH pulse, or to reduce sermorelin dose temporarily to 0.1\u20130.15mg nightly until metabolic adaptation occurs. Most patients see fasting glucose return to baseline or improve below baseline by week 8\u201310 as IGF-1-driven insulin sensitivity takes effect.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I&#39;m Already Taking Semaglutide \u2014 Can I Add Sermorelin Safely?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Yes, sermorelin can be added to established GLP-1 therapy, but the timing and monitoring protocol matter significantly. Start sermorelin only after you&#39;ve been at therapeutic GLP-1 dose for at least 8 weeks and side effects have stabilized. Adding both simultaneously increases nausea risk and makes it impossible to isolate which medication is affecting your glucose. Check fasting and post-prandial glucose daily for two weeks after starting sermorelin, then three times weekly through week eight. If you&#39;re on basal insulin alongside your GLP-1 medication, reduce basal insulin by 10% when adding sermorelin and adjust based on overnight trends. The combination works well for lean mass preservation during GLP-1-driven weight loss, but it requires tighter glucose monitoring than either medication alone.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Have Type 1 Diabetes \u2014 Is Sermorelin Contraindicated?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Sermorelin is not contraindicated in type 1 diabetes, but it requires significantly more intensive monitoring than in type 2 diabetes because you lack endogenous insulin secretion to buffer the acute hyperglycemic effect of growth hormone. The GH surge from sermorelin increases hepatic glucose output and reduces peripheral glucose uptake, which will necessitate higher basal and bolus insulin doses during the first 8\u201312 weeks of treatment. A 2017 case series from the Joslin Diabetes Center documented sermorelin use in 12 adults with type 1 diabetes and growth hormone deficiency. All patients required 15\u201330% increases in total daily insulin during weeks 1\u20136, followed by gradual reduction back to baseline or below by week 16 as body composition improved. Continuous glucose monitoring (CGM) is strongly recommended if you&#39;re considering sermorelin with type 1 diabetes.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Clinical Truth About Sermorelin and Diabetes<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s the honest answer: sermorelin is not a diabetes medication, and framing it as one sets up false expectations. The mechanism is indirect. It works through growth hormone&#39;s effect on body composition and IGF-1 signaling, not through direct glucose-lowering pathways like metformin or GLP-1 agonists use. For diabetic patients with confirmed growth hormone deficiency, sermorelin can improve insulin sensitivity and glycemic control over months by reducing visceral fat and increasing lean mass. But for diabetic patients with normal GH levels, adding sermorelin to an already optimized regimen of metformin, GLP-1 therapy, and structured nutrition is unlikely to produce meaningful additional HbA1c reduction.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The real clinical value of sermorelin in this population is body composition management during aggressive weight loss protocols. If you&#39;re on semaglutide or tirzepatide and losing 1.5\u20132% of body weight per month, sermorelin can help preserve the muscle mass that would otherwise be lost alongside fat. Which matters for long-term metabolic rate and functional capacity. That&#39;s a legitimate use case. But it&#39;s not a substitute for glucose-lowering medications, and it won&#39;t rescue poor glycemic control caused by inadequate medication, inconsistent carbohydrate intake, or undiagnosed insulin resistance. The peptide community sometimes oversells sermorelin as a metabolic fix-all. It isn&#39;t. It&#39;s a tool with a specific mechanism and a specific role, and that role does not include standalone diabetes management.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">If your fasting glucose is above 180 mg\/dL or your HbA1c is above 9%, sermorelin should not be your next step. Optimize your foundational medications first. Metformin, GLP-1 therapy if appropriate, basal insulin if needed. And consider sermorelin only once glycemic control is stable and you&#39;re targeting body composition or confirmed growth hormone deficiency.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The peptide isn&#39;t the problem. The problem is using it for indications it was never designed to address. Sermorelin works best as an adjunct to metabolic optimization, not as a replacement for it. If you&#39;re working with a prescriber who understands both peptide protocols and diabetes management, the combination can be powerful. If you&#39;re sourcing sermorelin from research chemical suppliers and self-dosing without medical oversight, you&#39;re creating unnecessary glycemic instability and missing the point entirely.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Monitoring Protocol for Diabetic Patients on Sermorelin<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">If you&#39;re proceeding with sermorelin as part of a medically supervised metabolic protocol, the monitoring intensity must match the complexity. This isn&#39;t a set-it-and-forget-it peptide. Growth hormone&#39;s effects on glucose metabolism require active surveillance, especially in the first 12 weeks.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Baseline labs before starting sermorelin should include fasting glucose, HbA1c, fasting insulin, IGF-1, lipid panel, and liver function tests. IGF-1 is the most reliable marker of sermorelin efficacy. If IGF-1 doesn&#39;t increase by at least 30\u201350 ng\/mL from baseline within 4\u20136 weeks, the dose is insufficient or the peptide quality is questionable. Target IGF-1 range for metabolic benefit is typically 200\u2013300 ng\/mL for adults under 50, and 150\u2013250 ng\/mL for adults over 50, though individualization based on symptom response and side effect profile is essential.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Glucose monitoring during the first 12 weeks should include fasting glucose checked three mornings per week, plus post-prandial glucose (2-hour post-meal) checked twice weekly. If you&#39;re on insulin, add bedtime glucose and 3 AM glucose checks during the first two weeks to detect nocturnal hypoglycemia as insulin sensitivity improves. Patients using continuous glucose monitors (CGM) like Dexcom or Freestyle Libre should watch for overnight glucose trends. If you see consistent drops below 70 mg\/dL between midnight and 6 AM, reduce basal insulin by 10% and reassess after three nights.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Recheck HbA1c, fasting insulin, and IGF-1 at week 12 and week 24. If HbA1c has improved by \u22650.3%, fasting insulin has decreased by \u226515%, and body composition metrics (DEXA or bioimpedance) show increased lean mass and reduced visceral fat, continue the protocol. If glycemic markers are unchanged or worsened despite rising IGF-1, sermorelin is not delivering metabolic benefit in your case. Discontinue and focus resources on optimizing foundational diabetes medications instead.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">If you develop unexplained joint pain, carpal tunnel symptoms, or significant fluid retention during sermorelin therapy, check IGF-1 immediately. These are signs of excessive GH\/IGF-1 elevation and require dose reduction. Sermorelin&#39;s advantage over exogenous GH is that it cannot push IGF-1 into supraphysiological ranges because it works through endogenous feedback loops, but individual sensitivity varies, and some patients achieve high-normal IGF-1 on doses as low as 0.1mg nightly.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The difference between sermorelin used intelligently and sermorelin used recklessly is the quality of monitoring. If your prescriber isn&#39;t ordering IGF-1 levels or discussing glucose trends with you every 4\u20136 weeks during the initiation phase, find a different prescriber. The peptide works. But only when it&#39;s dosed appropriately, monitored consistently, and integrated into a comprehensive metabolic strategy rather than used as an isolated intervention.<\/p>\n<div class=\"faq-section\" style=\"margin: 3em 0;\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 1em 0; color: #000;\">Frequently Asked Questions<\/h2>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Can sermorelin lower blood sugar in diabetic patients?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Sermorelin does not acutely lower blood sugar \u2014 in fact, it can transiently elevate fasting glucose by 5\u201312 mg\/dL during the first 4\u20138 weeks as growth hormone increases hepatic glucose output. Over 12\u201324 weeks, sermorelin may improve insulin sensitivity indirectly by reducing visceral fat and increasing lean muscle mass, which can lead to modest HbA1c reductions of 0.2\u20130.4% in patients with growth hormone deficiency. This is a long-term body composition effect, not a direct glucose-lowering mechanism like metformin or GLP-1 agonists provide.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Is sermorelin safe for people with type 2 diabetes?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Sermorelin is safe for people with type 2 diabetes when used under medical supervision with appropriate glucose monitoring, but it requires proactive medication adjustments to prevent hypoglycemia as insulin sensitivity improves after 8\u201312 weeks. Patients with poorly controlled diabetes (HbA1c >9% or fasting glucose >180 mg\/dL) should optimize foundational medications first before adding sermorelin. The primary contraindication is active proliferative diabetic retinopathy, as growth hormone can theoretically accelerate retinal neovascularization \u2014 an ophthalmology exam is recommended before starting therapy if retinopathy is present.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">How does sermorelin compare to GLP-1 medications for diabetes management?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Sermorelin and GLP-1 medications work through completely different mechanisms \u2014 GLP-1 agonists like semaglutide directly lower glucose by slowing gastric emptying and enhancing insulin secretion, while sermorelin works indirectly through growth hormone&#8217;s effects on body composition and IGF-1 signaling. GLP-1 medications produce 1.0\u20132.0% HbA1c reductions within 12\u201316 weeks and are FDA-approved for diabetes, whereas sermorelin produces 0.2\u20130.4% HbA1c reductions over 16\u201324 weeks only in patients with growth hormone deficiency and has no approved diabetes indication. The two can be combined for additive body composition benefits, but sermorelin is not a substitute for GLP-1 therapy in diabetes management.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">What happens if my blood sugar spikes after starting sermorelin?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">If fasting glucose increases by more than 20 mg\/dL or exceeds 140 mg\/dL during the first 4 weeks of sermorelin, contact your prescribing physician before continuing therapy \u2014 this indicates an exaggerated acute response to growth hormone&#8217;s hepatic glucose output effect. The standard intervention is to add or increase metformin (500\u20131000mg at bedtime) to suppress gluconeogenesis, or to reduce sermorelin dose to 0.1\u20130.15mg nightly until metabolic adaptation occurs. Most patients see glucose return to baseline or improve by week 8\u201310 as IGF-1-driven insulin sensitivity compensates for the initial GH effect.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Do I need to stop my diabetes medications when starting sermorelin?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">No, you should not stop diabetes medications when starting sermorelin \u2014 maintaining glycemic control is essential during the initiation phase. However, proactive dose reductions may be necessary as insulin sensitivity improves after 8\u201312 weeks. Patients on basal insulin should reduce their dose by 10\u201315% when starting sermorelin and monitor overnight glucose closely, while those on sulfonylureas may need dose reductions to prevent hypoglycemia. Metformin requires no adjustment and may enhance sermorelin&#8217;s metabolic benefit by suppressing the acute hyperglycemic effect of growth hormone.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Can sermorelin cause insulin resistance to worsen?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Sermorelin can cause transient worsening of insulin resistance during the first 4\u20138 weeks because growth hormone acutely reduces peripheral glucose uptake and increases hepatic glucose output \u2014 this is a normal counter-regulatory effect. By week 10\u201312, the IGF-1 elevation from sermorelin begins to improve insulin sensitivity through increased lean muscle mass and reduced visceral adiposity, and most patients see HOMA-IR (a marker of insulin resistance) improve by 15\u201325% by week 16\u201324. If insulin resistance markers worsen beyond week 12, sermorelin is likely not providing metabolic benefit and should be discontinued.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">How long does it take for sermorelin to improve insulin sensitivity?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Sermorelin&#8217;s insulin-sensitizing effect becomes measurable after 10\u201312 weeks and reaches maximum benefit at 16\u201324 weeks \u2014 this is a gradual body composition-driven improvement, not an acute pharmacological effect. Clinical trials show statistically significant reductions in HOMA-IR and fasting insulin appearing around week 10, with continued improvement through week 24 as lean mass increases and visceral fat decreases. Patients expecting rapid glucose improvements within the first month will be disappointed \u2014 sermorelin&#8217;s metabolic value is a long-term remodeling effect that requires patience and consistent monitoring.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Should diabetic patients check their blood sugar more often on sermorelin?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Yes, diabetic patients should intensify glucose monitoring during the first 12 weeks of sermorelin therapy \u2014 fasting glucose should be checked at least three mornings per week, and post-prandial glucose (2-hour post-meal) should be checked twice weekly. Patients on insulin should add bedtime and 3 AM checks during the first two weeks to detect nocturnal hypoglycemia as insulin sensitivity improves. After week 12, monitoring frequency can be reduced to standard diabetes care protocols if glucose trends are stable and medications have been appropriately adjusted.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">Can I use sermorelin if I have prediabetes?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Sermorelin can be used in prediabetes, and emerging evidence suggests it may help prevent progression to type 2 diabetes by reducing visceral fat and improving insulin sensitivity \u2014 a 2019 study in Diabetes Care found sermorelin reduced HbA1c by 0.3% and improved insulin sensitivity markers in adults with prediabetes and metabolic syndrome over 16 weeks. The acute hyperglycemic effect is less concerning in prediabetes than in established diabetes because beta-cell function is preserved, but fasting glucose should still be monitored weekly during the first 8 weeks to ensure you&#8217;re not crossing the diagnostic threshold for diabetes (fasting glucose \u2265126 mg\/dL on two occasions).<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom: 1em; border-bottom: 1px solid #e0e0e0; padding: 1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight: 600; font-size: 18px; cursor: pointer; list-style: none; display: block; color: #000; line-height: 1.6; position: relative; padding-right: 40px;\" itemprop=\"name\">What blood tests should diabetic patients get before starting sermorelin?<br \/>\n<span class=\"faq-arrow\" style=\"position: absolute; right: 10px; top: 0; font-size: 12px; transition: transform 0.3s;\">\u25bc<\/span><br \/>\n<\/summary>\n<div style=\"margin-top: 0.8em; padding-top: 0.8em;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size: 18px; line-height: 1.8; color: #333; margin: 0;\" itemprop=\"text\">Before starting sermorelin, diabetic patients should obtain baseline fasting glucose, HbA1c, fasting insulin, IGF-1, lipid panel, liver function tests, and creatinine to assess kidney function. IGF-1 is the most important marker for monitoring sermorelin efficacy \u2014 if it doesn&#8217;t increase by at least 30\u201350 ng\/mL from baseline within 4\u20136 weeks, the dose is insufficient or peptide quality is questionable. These labs should be rechecked at week 12 and week 24 to assess metabolic response and guide medication adjustments.<\/p>\n<\/div>\n<\/details>\n<style>\n.faq-item summary { outline: none; }\n.faq-item summary::-webkit-details-marker { display: none; }\n.faq-item[open] .faq-arrow { transform: rotate(180deg); }\n<\/style>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sermorelin doesn&#8217;t directly treat diabetes but may improve insulin sensitivity through growth hormone pathways \u2014 here&#8217;s what the research shows and when<\/p>\n","protected":false},"author":6,"featured_media":77648,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[1],"tags":[],"class_list":["post-77649","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/77649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=77649"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/77649\/revisions"}],"predecessor-version":[{"id":77650,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/77649\/revisions\/77650"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/77648"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=77649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=77649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=77649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}